The Business Development and Technology Transfer (BDTT) office serves as the bridge between cutting-edge research at The Lundquist Institute and real-world impact. We work with scientists, startups, and industry partners to protect and commercialize new technologies.
The BDTT team supports every step of the process from securing intellectual property, negotiating agreements, managing industry collaborations, to helping launch startups. Whether you’re looking to license a breakthrough discovery or co-develop a novel solution, the BDTT team is positioned to enable meaningful partnerships.
Key Functions
- Intellectual Property Protection
We work with TLI researchers to identify and protect promising inventions through patents, copyrights, and other forms of IP. - Technology Licensing
We license technologies to industry partners ranging from start-ups to established companies to ensure innovations reach the public. - Start-Up Support
We help researchers explore company formation by providing guidance on company structure, licensing, and connections to investors and incubators. - Industry and Research Collaborations
We facilitate partnerships between researchers and companies through sponsored research, collaboration agreements, confidentiality agreements (CDAs) and material transfer agreements (MTAs). - Commercial Strategy & Outreach
We evaluate the market potential of technologies, promote them to prospective partners, and negotiate deals that support further research and development. - Compliance and Research Support
Collaborate with TLI investigators to support their goals, manage potential conflicts, ensure compliance, and align their work with TLI’s mission.
FDA-Approved Products
Our innovative technologies are being commercially developed by various companies; examples include:
- Aldurazyme® enzyme replacement therapy for MPS 1
- Endari® for sickle cell disease
- Kybella® non-surgical injectable treatment for submental fullness
- Tepezza® for thyroid eye disease
- QT Medical PCA 500® electrocardiogram
Spin-off Companies
- QT Medical is developing the first, portable, medical grade mini ECG device – PCA500
- Vitalex Biosciences is developing a dual-antigen, cross kingdom vaccine that targets hospital-acquired infections caused by multidrug resistant Candida strains, and Gram-negative bacteria
- BDI is pioneering image analytics to diagnose diseases like Osteoporosis from routine, existing medical images.
Healthcare Innovations
$100MM
In technology transfer revenue in the past decade
$64MM
In federal and sponsored research funding
270+
Patents issued
840+
Patent applications
14
Start-up companies
50+
Proof of Concept
Meet Our BDTT Team
Meet the team behind The Lundquist Institute’s commercialization efforts of TLI’s 800+ patents and patent applications within the life sciences.
Innovations for Licensing
Explore technologies available for partnering across therapeutic, medical device, software, and diagnostic tool spaces.
BioLabs at The Lundquist Institute
18,000 square feet of flexible and state-of-the-art incubator and co-working spaces for life science startups to test, develop and grow game-changing ideas.
Partnerships and Licensing Opportunities
We are actively seeking to build on our history of successful collaborations with companies both large and small and are particularly interested in Industry sponsored research and partnerships.